The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects

British Journal of Clinical Pharmacology

Volumn 47, Issue 6, 1999, Pages 701-706

  Weber, Cornelia ^a,d   Banken, Ludger ^a   Birnboeck, Herbert ^b   Nave, Stephane ^c   Schulz, Rainer ^c  

^a Clinical Development   (Switzerland)

^b Preclinical Research   (Switzerland)

^c Clinical Pharmacology Unit   (France)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Digoxin; Drug drug interaction; Endothelial antagonists; Pharmacokinetics

Indexed keywords

BOSENTAN; DIGOXIN; ENDOTHELIN RECEPTOR ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGOXIN BLOOD LEVEL; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL;

CROSS-OVER STUDIES; DIGOXIN; DRUG INTERACTIONS; ENDOTHELIN-1; HUMANS; MALE; P-GLYCOPROTEIN; SULFONAMIDES;

EID: 0033035969     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00946.x     Document Type: Article

References (22)

1. 1 Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. 2 Noll G, Wenzel KR, Luescher TF. Endothelin and endothelin antagonists: Potential role in cardiovascular and renal disease. Molecular and Cellular Biochemistry 1996; 157: 259-267.
3. 3 Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in clinic. Trends Pharmacol Sci 1998; 19: 5-8.
4. 4 Clozel M, Breu V, Gray GA, et al. Pharmacological characterisation of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. Pharmacol Exp Ther 1994; 270: 228-235.
5. 5 Kiowski W, Suetsch G, Hunziker P, et al. Evidence of endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-736.
6. 6 Suetsch G, Kiowski W, Yan X-W, et al. Short-term endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (in press).
7. 7 Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996; 60: 124-137.
8. 8 Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H. Multiple dose pharmacokinetics, safety and tolerability of bosentan, an orally active endothelin receptor antagonist in healthy male volunteers. J Clin Pharmacol; (in press).
9. 9 Ubeaud G, Schmitt C, Jaeck D, Lave T, Coassolo Ph. Bosentan, a new endothelin-receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 1995; 25: 1381-1390.
10. 10 Roden D. Antiarrhytmic agents. In Goodman & Gilman's The pharmacological basis of therapeutics. Ninth edition, eds. Hardman JG, Limbird LE, Molinoff PB, Ruddon PW, Goodman Gilman A., New York: McGraw-Hill, 1996; 860-864.
11. 11 Aronson JK. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 1980; 5: 137-149.
12. 12 Cogan JJ, Humphreys MH, Carlson J, Benowitz NL, Rapaport E. Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. Circulation 1981; 64: 973-976.
13. 13 Ignasiak DP, McClanahan TB, Saganek LJ, Potoczak RE, Hallak H, Gallagher KP. Effects of endothelin receptor antagonism with PD 15607 on haemodynamics and renal vascular resistance in rabbits. Eur J Pharmacol 1997; 321: 295-300.
14. 14 Okamura N, Hirai M, Tanigawara Y, et al. Digoxin-cyclosporine A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993; 266: 1614-1619.
15. 15 Eggers H, Goetschi A, Masur S. Determination of the endothelin receptor antagonist bosentan in plasma by HPI.C-UV using a combined LLE/SPE procedure for sample purification. 1997, Abstract at HPLC '97, Birmingham, UK.
16. 16 Clavell AL, Burnett JC. Physiologic and pathophysiologic roles of endothelin in the kidney. Curr Opin in Nephrol Hypertension 1994; 3: 66-72.
17. 17 Pernow J, Boutier JF, Franco Ceredeca A, Lacroix JS, Matran R, Lundberg JM. Potent selective vasoconstrictor effects of endothelin in the pig kidney in vivo. Acta Physiol Scand 1988; 134: 573-574.
18. 18 Maguire JJ, Kuc RE, O'Reilly G, Davenport AD. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vivo. Br J Pharmacol 1994; 113: 49-54.
19. 19 Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology. Kidney Int 1994; 46: 376-381.
20. 20 Koren G. Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin Pharmacokinet 1987; 13: 334-343.
21. 21 Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993; 266: 1620-1625.
22. 22 Ito S, Woodland C, Harper PA, Koren G. P-glycoprotein-mediated renal tubular secretion of digoxin: The toxicological significance of the urine blood barrier model. Ljfe Sci 1993; 53: 25-31.